Inogen (NASDAQ: INGN)
Inogen Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Inogen Company Info
Inogen, Inc. is a medical technology company, which engages in the development, manufacture, and marketing of portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. Its products include Inogen One G4 system, Inogen One G3 system, Inogen One G5 system, Inogen TAV, and Inogen at Home. The company was founded by Alison Perry, Alison K. Bauerlein, Brenton Taylor, and Byron Myers on November 27, 2001 and is headquartered in Goleta, CA.
News & Analysis
Wall Street Has Given Up on These 3 Stocks, and That's a Huge Mistake
Big declines in stock price may bring big opportunities for patient investors.
Why Inogen Shareholders Are Having Another Tough Day
Shares sink after the medical-device maker reported weak second-quarter results and slashed guidance. Again.
3 Top Healthcare Stocks to Buy in July
Find out which stocks have our team of healthcare experts feeling excited right now.
Why Inogen Shares Are Plunging Today
The stock sinks after the medical device marker slashes its full-year guidance.
Interview: Talking Decking, Diets, and Discounts With the Polen Small Company Growth Team
John talks to Tucker Walsh and Rayna Lesser Hannaway, the two portfolio managers of the Polen U.S. Small Company Growth Strategy, about Paycom, EPAM Systems, and more.
Here's Why Inogen Fell As Much As 28.2% Today
The medical technology company issued fourth-quarter and full-year 2018 earnings.
Down 50% in 2 Months, Is Inogen Stock a Buy? 1 Analyst Thinks So
Inogen stock got crushed in the tech rout, giving investors a second bite at the apple.
1 Little Known Healthcare Stock to Put on Your Radar
This healthcare company is growing fast and is up 400% over last three years. Here's why investors can expect the good times to continue.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.